Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)
Hong Kong · Delayed Price · Currency is HKD 3.850
+0.010 (0.26%)
Sep 18, 2026, 4:08 PM HKT
HKG:2591 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cash & Equivalents | 847.1 | 969.09 | 526.51 | 157.64 |
Short-Term Investments | 34.06 | 105.43 | 45.15 | 42.55 |
Trading Asset Securities | 141.7 | 130 | 225.19 | 495.13 |
Cash & Short-Term Investments | 1,023 | 1,205 | 796.85 | 695.31 |
Cash Growth | 39.36% | 51.16% | 14.60% | - |
Accounts Receivable | 10.72 | 5.56 | - | - |
Other Receivables | 52.92 | 137.33 | 7.73 | 1.34 |
Receivables | 63.64 | 142.88 | 7.73 | 1.34 |
Inventory | 114.38 | 115.94 | 29.04 | 3.45 |
Other Current Assets | 7.02 | 15.64 | 5.6 | 257.38 |
Total Current Assets | 1,208 | 1,479 | 839.22 | 957.48 |
Property, Plant & Equipment | 36.31 | 35.18 | 13.3 | 54.85 |
Other Intangible Assets | 19.84 | 21.58 | 24.09 | 35.87 |
Other Long-Term Assets | 35.75 | 35.27 | 58.19 | 57.17 |
Total Assets | 1,300 | 1,571 | 934.8 | 1,105 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Accounts Payable | 133.86 | 225.08 | 91.05 | 88.33 |
Accrued Expenses | 30.74 | 86.87 | 29.95 | 14.51 |
Short-Term Debt | 134.12 | 150.26 | 9.9 | 1 |
Current Portion of Leases | 4.89 | 3.04 | - | 4.82 |
Current Unearned Revenue | 0.06 | - | 1 | - |
Other Current Liabilities | 41.9 | 39.34 | 6.37 | 250.74 |
Total Current Liabilities | 345.57 | 504.58 | 138.26 | 359.4 |
Long-Term Leases | 12.21 | 12.96 | - | 40.76 |
Other Long-Term Liabilities | 0.07 | 0.07 | 0.07 | 0.07 |
Total Liabilities | 357.85 | 517.61 | 138.33 | 400.24 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Common Stock | 456.82 | 456.82 | 420.26 | 397.67 |
Additional Paid-In Capital | - | 1,811 | 1,264 | 1,037 |
Retained Earnings | - | -1,839 | -1,497 | -1,323 |
Comprehensive Income & Other | 485.14 | 623.8 | 609.28 | 593.24 |
Shareholders' Equity | 941.95 | 1,053 | 796.47 | 705.13 |
Total Liabilities & Equity | 1,300 | 1,571 | 934.8 | 1,105 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Total Debt | 151.22 | 166.26 | 9.9 | 46.59 |
Net Cash (Debt) | 871.64 | 1,038 | 786.95 | 648.73 |
Net Cash Growth | 28.74% | 31.94% | 21.31% | - |
Net Cash Per Share | 1.93 | 2.39 | 1.88 | 1.69 |
Filing Date Shares Outstanding | 456.82 | 456.82 | 420.26 | 382.8 |
Total Common Shares Outstanding | 456.82 | 456.82 | 420.26 | 382.8 |
Working Capital | 862.33 | 974.4 | 700.96 | 598.07 |
Book Value Per Share | 2.06 | 2.31 | 1.90 | 1.84 |
Tangible Book Value | 922.12 | 1,032 | 772.38 | 669.26 |
Tangible Book Value Per Share | 2.02 | 2.26 | 1.84 | 1.75 |
Machinery | - | 28.08 | 24.56 | 22.43 |
Construction In Progress | - | 0.52 | - | 4.45 |
Leasehold Improvements | - | 5.48 | 0.15 | - |